0000950170-24-042322.txt : 20240405
0000950170-24-042322.hdr.sgml : 20240405
20240405164530
ACCESSION NUMBER: 0000950170-24-042322
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240403
FILED AS OF DATE: 20240405
DATE AS OF CHANGE: 20240405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SMITH IAN F
CENTRAL INDEX KEY: 0001197032
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38360
FILM NUMBER: 24827095
MAIL ADDRESS:
STREET 1: C/O ACORDA THERAPEUTICS, INC.
STREET 2: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Solid Biosciences Inc.
CENTRAL INDEX KEY: 0001707502
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 900943402
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 RUTHERFORD AVENUE
STREET 2: 3RD FLOOR
CITY: CHARLESTOWN
STATE: MA
ZIP: 02129
BUSINESS PHONE: 617-337-4680
MAIL ADDRESS:
STREET 1: 500 RUTHERFORD AVENUE
STREET 2: 3RD FLOOR
CITY: CHARLESTOWN
STATE: MA
ZIP: 02129
FORMER COMPANY:
FORMER CONFORMED NAME: Solid Biosciences, LLC
DATE OF NAME CHANGE: 20170524
4
1
ownership.xml
4
X0508
4
2024-04-03
0001707502
Solid Biosciences Inc.
SLDB
0001197032
SMITH IAN F
C/O SOLID BIOSCIENCES INC.
500 RUTHERFORD AVENUE, THIRD FLOOR
CHARLESTOWN
MA
02129
true
false
false
false
false
Common Stock
2024-04-03
4
M
false
3256
A
103207
D
Restricted Stock Units
2024-04-03
4
M
false
3256
0
D
Common Stock
3256
9765
D
Restricted stock units convert into common stock on a one-for-one basis.
The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.
/s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith
2024-04-05